Michael J. Fox Foundation Grants $6.9 Million to Prepare OPM-201 Therapy for 2027 Clinical Trials

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a $6.92 million grant to Oncodesign Precision Medicine (OPM) to accelerate the development of a promising new treatment candidate. The funding is specifically aimed at preparing OPM-201, a potential disease-modifying therapy, for upcoming clinical trials involving people in the early stages of the Parkinson's condition. The treatment focuses on a protein called LRRK2, which is linked to one of the most common genetic causes of the condition. In many people, mutations in the LRRK2 gene lead to an overactive protein that disrupts how cells communicate and clear out waste. OPM-201 is an oral small-molecule therapy designed to block this excessive activity, potentially protecting the nerve cells that produce dopamine from further damage. This significant financial boost follows the integration of OPM into the foundation’s LRRK2 Investigative Therapeutics Exchange (LITE) programme. This initiative allows researchers and industry experts to share data and tools, ensuring that the most promising ideas move toward the clinic as quickly as possible. Experts from the LITE advisory team have already reviewed OPM’s data in great detail, confirming that the drug is both potent and highly selective, meaning it targets the intended protein without interfering with others. Earlier Phase 1 trials involving healthy volunteers have already shown that OPM-201 is safe and well-tolerated. This new grant will now cover the critical "behind-the-scenes" work necessary to move to the next level. This includes refining the manufacturing process to produce the tablets needed for the studies and conducting long-term toxicology research required by regulators before Phase 2 and Phase 3 trials can begin. If these preparatory steps are successful, the company intends to launch Phase 1b and Phase 2 clinical studies in 2027. By focusing on these specific genetic pathways, researchers hope to offer a treatment that does more than manage symptoms, aiming instead to fundamentally change the progression of the condition for those in urgent need of new options.